Newswise — This past October, 214 researchers from the U.S., Europe, and Australia, as well as representatives of families with aggressive genetic forms of Alzheimer disease (AD), met at Washington University, St. Louis, Missouri, to devote two intense days of talks and discussion to their goal of detecting this disease before symptoms appear. By a growing consensus, defining the “silent” phase of AD has become the field’s central challenge if it is to modernize drug testing and lay the groundwork for AD prevention trials.
Presymptomatic carriers of deterministic AD mutations arguably harbor a unique potential to solve this challenge for all of AD. The St. Louis conference pulled together the latest research advances in this area. More than that, it also served as a chance for the far-flung participants in the Dominantly Inherited Alzheimer Network (DIAN) to push their ambitious project forward. In short, initial numbers on enrollment, passionate family input on counseling, community building and data privacy, and budding plans to offer a clinical trial to participating families were the main upshot of these conversations.
The Alzheimer Research Forum's Gabrielle Strobel reports on this landmark meeting in a seven-part series. The stories are:
Scientists, Families Target Preclinical Detection, TrialsThe Family View—What Do Study Volunteers Want From DIAN?Cognition Pre-dementia—Like eFAD, Like LOAD?Biomarkers Pre-dementia—Like eFAD, Like LOAD?Is Rare Familial Alzheimer’s a Model for the Millions?Imaging Preclinical AD—Can You See it Coming in the Brain?An eFAD Prevention Trial—One Man’s View
To read the full report, go to:http://www.alzforum.org/new/detail.asp?id=2264
The Alzheimer Research Forum (www.alzforum.org), founded in 1996, is the web's most dynamic scientific community dedicated to understanding Alzheimer disease and related disorders. Access to the web site is free to all. The Forum’s editorial priorities are as diverse as the needs of the research community. The web site reports on the latest scientific findings, from basic research to clinical trials; creates and maintains public databases of essential research data and reagents; and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across the numerous disciplines that can contribute to the global effort to cure Alzheimer's disease.
The ARF team of professional science writers and editors, information technology experts, web developers and producers all work closely with its distinguished and diverse Advisory Board to ensure a high quality of information and services. The Alzheimer Research Forum is an independent nonprofit organization supported by grants and individual donations. The web site does not endorse any specific product or scientific approach.
RSS